Table 1 Baseline characteristics of FM

Female n;(%)

41 (49.4)

6 (42.9)

35 (50.7)

age (year) Median [Q1, Q3]

37 [29,48]

42.5 [32.75,50.75]

37 [27,47.5]

Premonitory symptoms of viral infection n;(%)

63 (75.9)

10 (71.4)

53 (76.8)

Co-existing conditions n;(%)

Hypertension

6 (7.2)

1 (7.1)

5 (7.2)

 Diabetes mellitus

4 (4.8)

0

4 (5.8)

 Renal disease

1 (1.2)

1 (7.1)

0

Time from onset to admission (days) Median [Q1, Q3]

3 [2, 5]

4.5 [2.75,10.25]

3 [1, 4.5]

Coronary angiography (n, %)

36 (43.3)

4 (28.6)

32 (46.4)

CMR (n,%)

29 (34.9)

0

29 (42.0)

Clinical symptoms n;(%)

 Chest pain

19 (22.9)

2 (14.3)

17 (24.6)

 Chest distress

58 (69.9)

10 (71.4)

48 (69.6)

 Palpitation

19 (22.9)

3 (21.4)

16 (23.2)

 Dizziness

21 (25.3)

2 (14.3)

19 (27.5)

 Disturbances of consciousness

18 (21.7)

3 (21.4)

15 (21.7)

Ejection fraction at lowest (x ± s)

33.7 ± 13.5

40.9 ± 15.3

32.5 ± 13.0

ECG n;(%)

 ST-segment elevation

30 (36.1)

4 (28.6)

26 (37.7)

 Ventricular tachycardia or ventricular fibrillation

12 (14.5)

5 (35.7)

7 (10.1)

 Atrioventricular block

14 (16.9)

2 (14.3)

12 (17.4)

ALT(U/L) Median [Q1, Q3]

85 [44,408]

286 [48,1379]

70 [42.5,318]

Crea(umol/l) Median [Q1, Q3])

74 [57,116]

160 [83,331]

71 [48,101]

Vasoactive agent n;(%)

60 (72.3)

14 (100)

46 (66.7)

Anti-viral therapy n;(%)

81 (97.6)

12 (85.7)

69 (100)

Glucocorticoid therapy n;(%)

83 (100)

14 (100)

69 (100)

IVIG n;(%)

73 (88.0)

8 (57.1)

65 (94.2)

Mechanical ventilation n;(%)

32 (38.6)

7 (50.0)

25 (36.2)

IABP n;(%)

67 (80.7)

7 (50.0)

60 (87.0)

ECMO n;(%)

19 (22.9)

3 (21.4)

16 (23.2)

IABP + ECMO n;(%)

17 (20.5)

3 (21.4)

14 (20.3)